You are here

  • Home
  • Archive
  • Volume 79, Issue 9
  • Response to: ‘Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis’ by Sugiyama

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis’ by Sugiyama
Free
  1. Gulsen Ozen1,
  2. Kaleb Michaud1,2
  1. 1 University of Nebraska Medical Center, Omaha, Nebraska, USA
  2. 2 FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, USA
  1. Correspondence to Dr Kaleb Michaud, FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS 67214, USA; kmichaud{at}unmc.edu

http://dx.doi.org/10.1136/annrheumdis-2019-215775

Statistics from Altmetric.com

    We appreciate the interest shown by Dr Sugiyama1 concerning our recent study on medications associated with fracture risk in patients with rheumatoid arthritis (RA).2 He emphasises the lack of association between proton pump inhibitor (PPI) use and fracture risk in patients with RA, which has been a conflicting issue for the general population. We agree that the previous studies showing an increased fracture risk with PPIs in the general population may be confounded by the indication as it is known that PPI …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

    Linked Articles